文献速递胸部肿瘤放疗

立体定向消融放疗用于不适合同步放化疗的新诊断及复发局部晚期非小细胞肺癌患者:START-NEW-ERA 非随机 II 期试验早期分析

STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-24

这项单臂 II 期试验纳入 50 例不可切除、不适合同步放化疗的局部晚期非小细胞肺癌患者,评估立体定向消融放疗的局部控制与安全性。中位随访 38 个月,1、2、3 年局部无复发生存率分别为 86%±5%、66%±7%、56%±8%,总生存率分别为 94%±3%、79%±6%、72%±7%,无患者发生≥3 级毒性。

要点

  • 50 例不适合同步放化疗的局部晚期非小细胞肺癌患者接受立体定向消融放疗,无≥3 级毒性发生。
  • 中位随访 38 个月,1、2、3 年局部无复发生存率分别为 86%±5%、66%±7%、56%±8%。
  • 中位总生存 55 个月(95%CI 43-55 个月),腺癌与更好的局部控制相关(HR 3.61,95%CI 1.15-11.35)。

核心结论

  • 接受立体定向消融放疗的局部晚期非小细胞肺癌患者获得最佳局部控制且有希望的总生存,未发生≥3 级毒性。
  • 作者认为早期结果提示该方法在不适合同步放化疗的局部晚期非小细胞肺癌患者中具有可行性。

研究设计与样本

  • 单臂 II 期试验(ClinicalTrials.gov NCT05291780),评估立体定向消融放疗在不可切除、不适合同步放化疗的局部晚期非小细胞肺癌患者中的局部控制与安全性。
  • 2015年12月31日至2020年12月31日共入组 50 例局部晚期非小细胞肺癌患者。
  • 适合的患者接受新辅助化疗;肿瘤体积包括原发灶及任何区域阳性淋巴结。
  • 共同主要研究终点为局部控制和安全性。

主要发现

  • 组织学为鳞状细胞癌和腺癌者分别占 52% 和 48%;40 例(80%)为超中央型肿瘤。
  • 27 例(54%)接受新辅助化疗,7 例(14%)接受辅助度伐利尤单抗。
  • 肿瘤中位处方剂量为 45 Gy(范围 35-55),淋巴结中位处方剂量为 40 Gy(范围 35-45),均为每日 5 次分割。
  • 中位随访 38 个月(范围 12-80),19 例(38%)出现局部复发,中位时间 13 个月(范围 7-34)。
  • 中位局部无复发生存未达到(95%CI 28 至未达到);1、2、3 年局部无复发生存率分别为 86%±5%、66%±7%、56%±8%。

临床怎么用

  • 作者认为早期结果提示,对不适合同步放化疗的局部晚期非小细胞肺癌患者使用立体定向消融放疗具有可行性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This is a single arm phase 2 trial (Clinical trials.gov NCT05291780) to assess local control (LC) and safety of SAbR in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) unfit for concurrent chemo-radiation therapy (ChT-RT). METHODS: Neoadjuvant ChT was prescribed in fit patients. The tumor volume included primary tumor and any regionally positive node/s. The coprimary study endpoints were LC and safety. RESULTS: Between December 31, 2015, and December 31, 2020, 50 patients with LA-NSCLC were enrolled. Histology was squamous cell carcinoma and adenocarcinoma (ADC) in 52% and 48%, respectively. Forty (80%) patients had ultracentral tumor. Twenty-seven (54%) received neoadjuvant ChT and 7 (14%) adjuvant durvalumab. Median prescribed dose was 45 Gy (range, 35-55) and 40 Gy (35-45) in 5 daily fractions to tumor and node/s, respectively. After a median follow-up of 38 months (range, 12-80), 19 (38%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7-34). The median LR-free survival (FS) was not reached (95% confidence interval [CI], 28 to not reached). The 1-, 2-, and 3-year LR-FS rates were 86% ± 5%, 66% ± 7%, and 56% ± 8%, respectively. At last follow-up, 33 (66%) patients were alive. Median overall survival (OS) was 55 months (95% CI, 43-55 months). The 1-, 2-, and 3-year OS rates were 94% ± 3%, 79% ± 6%, and 72% ± 7%, respectively. No patients developed ≥ grade (G) 3 toxicity. ADC (hazard ratio [HR], 3.61; 95% CI, 1.15-11.35) was a significant predictor of better LC, while OS was significantly conditioned by smaller planning target volumes (HR, 1.004; 95% CI, 1.001-1.010) and tumor, node, and metastasis stage (HR, 4.8; 95% CI, 1.34-17). CONCLUSIONS: Patients with LA-NSCLC treated with SABR had optimal LC and promising OS in absence of ≥G3 toxicity. Our early outcomes would suggest the feasibility of using this approach in patients with LA-NSCLC unfit for concurrent ChT-RT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Arcidiacono F, Anselmo P, Casale M, et al. STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 36288758. doi:10.1016/j.ijrobp.2022.10.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。